Preclinical to market (drug development II) 01

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/19

encourage image

There's no tags or description

Looks like no tags are added yet.

20 Terms

1
New cards

Investigational New Drug (IND) application

  • After enough preclinical development, an IND application can be submitted to FDA

  • Allows sponsor to propose beginning clinical trials in humans

  • FDA reviews submission before proposed clinical study proceeds


2
New cards

The IND includes info on…

  • Pharmacology and toxicology

  • Manufacturing and formulation

  • Proposed clinical trial protocols

  • Clinical investigator information


3
New cards

Clinical trials

- Studies conducted on human participants according to an approved clinical trial protocol

- Evaluate safety, dose, efficacy

- Progress thru Phases I to III

4
New cards

Double blind studies

- Participants don't know their treatment assignment

- Investigators involved in treatment/assessment don't know the assignment

5
New cards

Components of double blind studies

- Compare treatment groups: investigational drug vs. placebo/active treatment

- Placebo effect: must be scien+ethically appropriate

- Helps reduce bias

6
New cards

Nuremberg code (1947)

- Developed following the Nuremberg Doctors' trials after WW2

- Responded to unethical human experimentation

- Established fundamental principles for ethical research involving humans

- Foundation of modern research ethics

7
New cards

Key principles of Nuremberg code

- Voluntary participiation

- Informed consent

- Risks justified by potential benefits

8
New cards

Modern clinical research ethics

- Declaration of Helsinki

- Good clinical practice (GCP)

- Ethics committee

- Informed consent

- Applicable national reg's

9
New cards

Regulatory oversight of drug development

- Regulatory agencies oversee drug development & clinical trials

- Help ensure safety, efficacy & quality standards

- Review reg. submissions & trial data

- Major authorities: FDA, Health Canada

10
New cards

Phase I clinical trials

- 20-100 (often healthy) participants

- Focus on safety, dose, pharmacokinetics (PK)

- 70% proceed to Phase II

- Duration: months to 1 yr

11
New cards

Phase II clinical trials

- 100's (diseased/condition) patients

- Focus on efficacy, dose, safety

- 30% proceed to Phase III

- Duration months to 2 yrs

12
New cards

Phase III clinical trials

- 300-3000 patients (in target patient popu)

- Focus on confirming efficacy, safety, identifying less common adverse effects

- 25-30% proceed to regulatory submission

- Duration: 1-4 yrs

13
New cards

New drug application (NDA)

- Formal application to FDA requesting approval to market new drug

- Includes pre+clinical data, safety, labeling

- FDA review timeline includes priority & standard review

- Modern submission r electronic

14
New cards

Post-approval (Phase IV)

- Drug enters wider clinical use

- Postmarketing safety surveillance

- Continued development may investigate new indications

- May evaluate long-term safety, drug int's

15
New cards

New safety info may lead to... (Phase IV)

- Labeling changes

- Extra studies/restrictions

16
New cards

Orphan drugs

- Drugs developed for rare diseases or conditions

- Development challenges: small patient popu's, hard to recruit ppl

- US incentives: tax credits, waiver of some FDA fees

17
New cards

Theory of teratogenicity for thalidomide

  • Based on animal experiments in 1970’s

  • D was sold as a racemate: S enantiomer was teratogenic → vasoconstrictor

  • Difficult to reprod the exp

    • Enantiomer effect requires i.p. dosing (injection)

    • Racemization of the D


<ul><li><p>Based on animal experiments in 1970’s </p></li><li><p>D was sold as a racemate: S enantiomer was teratogenic → vasoconstrictor </p></li><li><p>Difficult to reprod the exp</p><ul><li><p>Enantiomer effect requires i.p. dosing (injection) </p></li><li><p>Racemization of the D</p></li></ul></li></ul><p></p>
18
New cards

FDA oversight of drugs

  • Sponsors generate & submit data

  • FDA reviews evidence & conducts inspections

  • After approval, continued safety monitoring, comapanies report adverse-event info


19
New cards

Benefits of industry regulation

  • Ensure safe, effective & consistent quality products

  • Provides consumer protection


20
New cards

Challenges of industry regulation

  • Adds time & cost to D development

  • Regulatory requirements can affect speed of access

  • Requires extensive documentation & oversight